Compugen to present ovarian cancer trial data at ESMO congress

Compugen Ltd. (NASDAQ: CGEN) will present a trial-in-progress poster on its MAIA-ovarian Phase 1 study at the ESMO Gynaecological Cancers Congress 2026, according to a company statement.

The poster presentation will take place June 18, 2026, from 12:45 to 13:30 CEST in Copenhagen, Denmark. Dr. Oladapo Yeku from Massachusetts General Hospital in Boston will present the data.

The MAIA-ovarian study evaluates COM701, an anti-PVRIG antibody, as maintenance treatment in patients with relapsed platinum-sensitive ovarian cancer. The trial is registered under NCT06888921 and represents an adaptive platform clinical trial design.

COM701 is being developed as a potential treatment for solid tumors and has been studied both as a single agent and in combination therapies. The company describes it as a potential first-in-class anti-PVRIG antibody.

Compugen is a clinical-stage cancer immunotherapy company based in Holon, Israel, that uses computational methods powered by artificial intelligence and machine learning to identify drug targets. The company's pipeline includes four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321.

Following the congress presentation, the poster will be made available on Compugen's website. The ESMO Gynaecological Cancers Congress runs from June 17 to June 19, 2026.

You May Also Be Interested In

• FTI Consulting names Jerome Nyssen senior managing director in Australia
• Isoplus selects Navan to manage global travel and expense program
• Taysha Gene Therapies (TSHA) PT Raised to $11 at Citizens on REVEAL Data Update